{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:12:58Z","timestamp":1795180378906,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93518-z","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:49:41Z","timestamp":1741765781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Chunbo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"7","key":"93518_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter, T.G. & Rinella, M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology 158(7), 1851\u20131864. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.052 (2020).","journal-title":"Gastroenterology"},{"issue":"4","key":"93518_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan, N., H\u00e4ring, H. U. & Cusi, K. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 7(4), 313\u2013324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30154-2 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"93518_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73\u201384. https:\/\/doi.org\/10.1002\/hep.28431 (2016).","journal-title":"Hepatology"},{"issue":"8","key":"93518_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/apt.16575","volume":"54","author":"SA Polyzos","year":"2021","unstructured":"Polyzos, S. A., Kechagias, S. & Tsochatzis, E. A. Review article: Non-alcoholic fatty liver disease and cardiovascular diseases: Associations and treatment considerations. Aliment. Pharmacol. Ther. 54(8), 1013\u20131025. https:\/\/doi.org\/10.1111\/apt.16575 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"93518_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24(7), 908\u2013922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9 (2018).","journal-title":"Nat. Med."},{"issue":"5","key":"93518_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","volume":"21","author":"HS Bhatia","year":"2024","unstructured":"Bhatia, H. S. et al. Lipoprotein(a), platelet function and cardiovascular disease. Nat. Rev. Cardiol. 21(5), 299\u2013311. https:\/\/doi.org\/10.1038\/s41569-023-00947-2 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"93518_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2022.09.010","volume":"106","author":"ZW Wang","year":"2022","unstructured":"Wang, Z. W., Li, M., Li, J. J. & Liu, N. F. Association of lipoprotein(a) with all-cause and cause-specific mortality: A prospective cohort study. Eur. J. Intern. Med. 106, 63\u201370. https:\/\/doi.org\/10.1016\/j.ejim.2022.09.010 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"93518_CR8","doi-asserted-by":"publisher","unstructured":"Duarte Lau, F. & Giugliano, R. P. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review [published correction appears in JAMA Cardiol. ;7(7):776. (2022). https:\/\/doi.org\/10.1001\/jamacardio.2022.2074]. JAMA Cardiol. 7(7), 760\u2013769 https:\/\/doi.org\/10.1001\/jamacardio.2022.0987 (2022).","DOI":"10.1001\/jamacardio.2022 10.1001\/jamacardio.2022.0987"},{"issue":"1","key":"93518_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1186\/s12889-024-19443-4","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Yan, X., Fang, L., Tang, J. & Zhang, J. Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: Findings from the NHANES. BMC Public. Health. 24(1), 1927. https:\/\/doi.org\/10.1186\/s12889-024-19443-4 (2024). Published 2024 Jul 18.","journal-title":"BMC Public. Health"},{"issue":"6","key":"93518_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas, S. A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69(6), 692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"93518_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt, K., Noureen, A., Kronenberg, F. & Utermann, G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57(8), 1339\u20131359. https:\/\/doi.org\/10.1194\/jlr.R067314 (2016).","journal-title":"J. Lipid Res."},{"issue":"50","key":"93518_CR12","doi-asserted-by":"publisher","first-page":"20105","DOI":"10.1021\/acs.jafc.3c06498","volume":"71","author":"C Fan","year":"2023","unstructured":"Fan, C. et al. Nobiletin ameliorates hepatic lipid deposition, oxidative stress, and inflammation by mechanisms that involve the Nrf2\/NF-\u03baB Axis in nonalcoholic fatty liver disease. J. Agric. Food Chem. 71(50), 20105\u201320117. https:\/\/doi.org\/10.1021\/acs.jafc.3c06498 (2023).","journal-title":"J. Agric. Food Chem."},{"issue":"3","key":"93518_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62(3), 720\u2013733. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039 (2015).","journal-title":"J. Hepatol."},{"key":"93518_CR14","doi-asserted-by":"publisher","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","volume":"14","author":"H Peng","year":"2023","unstructured":"Peng, H. et al. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. Adults. Front. Endocrinol. (Lausanne). 14, 1083032. https:\/\/doi.org\/10.3389\/fendo.2023.1083032 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"24","key":"93518_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","volume":"54","author":"FC Bull","year":"2020","unstructured":"Bull, F. C. et al. World health organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 54(24), 1451\u20131462. https:\/\/doi.org\/10.1136\/bjsports-2020-102955 (2020).","journal-title":"Br. J. Sports Med."},{"issue":"19","key":"93518_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian, A. V. et al. The seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA 289(19), 2560\u20132572. https:\/\/doi.org\/10.1001\/jama.289.19.2560 (2003).","journal-title":"JAMA"},{"key":"93518_CR17","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1), S17\u2013S38 https:\/\/doi.org\/10.2337\/dc22-S002 (2022).","DOI":"10.2337\/dc22-S002"},{"key":"93518_CR18","doi-asserted-by":"publisher","unstructured":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 2020;292:160\u2013162. doi: 10.1016\/j.atherosclerosis.2019.11.020] [published correction appears in Atherosclerosis. 2020;294:80\u201382. doi: 10.1016\/j.atherosclerosis.2019.12.004]. Atherosclerosis. 2019;290:140\u2013205. (2019). https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"issue":"32","key":"93518_CR19","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic, I. et al. Transient elastography (FibroScan(\u00ae)) with controlled Attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J. Gastroenterol. 22(32), 7236\u20137251. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7236 (2016).","journal-title":"World J. Gastroenterol."},{"issue":"28","key":"93518_CR20","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","volume":"20","author":"S Mili\u0107","year":"2014","unstructured":"Mili\u0107, S., Luli\u0107, D. & \u0160timac, D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J. Gastroenterol. 20(28), 9330\u20139337. https:\/\/doi.org\/10.3748\/wjg.v20.i28.9330 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"93518_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/CM9.0000000000002753","volume":"137","author":"M Yuan","year":"2024","unstructured":"Yuan, M. et al. Hypertension and NAFLD risk: Insights from the NHANES 2017\u20132018 and Mendelian randomization analyses. Chin. Med. J. (Engl). 137(4), 457\u2013464. https:\/\/doi.org\/10.1097\/CM9.0000000000002753 (2024).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"11","key":"93518_CR22","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/ijms21113863","volume":"21","author":"H Fujii","year":"2020","unstructured":"Fujii, H. (ed Kawada, N.) Japan Study Group Of Nafld Jsg-Nafld The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 21 11 3863 https:\/\/doi.org\/10.3390\/ijms21113863 (2020). Published 2020 May 29.","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"93518_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cmet.2023.08.001","volume":"35","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q., Yu, L., Cook, J. R., Qiang, L. & Sun, L. Deciphering the decline of metabolic elasticity in aging and obesity. Cell. Metab. 35(9), 1661\u20131671e6. https:\/\/doi.org\/10.1016\/j.cmet.2023.08.001 (2023).","journal-title":"Cell. Metab."},{"key":"93518_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.metabol.2018.11.005","volume":"92","author":"J Vekic","year":"2019","unstructured":"Vekic, J., Zeljkovic, A., Stefanovic, A., Jelic-Ivanovic, Z. & Spasojevic-Kalimanovska, V. Obesity and dyslipidemia. Metabolism 92, 71\u201381. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.005 (2019).","journal-title":"Metabolism"},{"issue":"1","key":"93518_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/ALN.0b013e3181799d45","volume":"109","author":"JA Martyn","year":"2008","unstructured":"Martyn, J. A., Kaneki, M. & Yasuhara, S. Obesity-induced insulin resistance and hyperglycemia: Etiologic factors and molecular mechanisms. Anesthesiology 109(1), 137\u2013148. https:\/\/doi.org\/10.1097\/ALN.0b013e3181799d45 (2008).","journal-title":"Anesthesiology"},{"issue":"1","key":"93518_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55(1), 31\u201355. https:\/\/doi.org\/10.1016\/j.immuni.2021.12.013 (2022).","journal-title":"Immunity"},{"issue":"6","key":"93518_CR27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/jcp.31019","volume":"238","author":"D Aboukhater","year":"2023","unstructured":"Aboukhater, D. et al. Inflammation and hypertension: Underlying mechanisms and emerging Understandings. J. Cell. Physiol. 238(6), 1148\u20131159. https:\/\/doi.org\/10.1002\/jcp.31019 (2023).","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"93518_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/HYPERTENSIONAHA.117.07802","volume":"70","author":"TJ Guzik","year":"2017","unstructured":"Guzik, T. J. & Touyz, R. M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 70(4), 660\u2013667. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.07802 (2017).","journal-title":"Hypertension"},{"key":"93518_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2016.07.003","volume":"461","author":"JS Nam","year":"2016","unstructured":"Nam, J. S. et al. Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. Clin. Chim. Acta. 461, 14\u201318. https:\/\/doi.org\/10.1016\/j.cca.2016.07.003 (2016).","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"93518_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jacl.2023.09.003","volume":"17","author":"A Mehta","year":"2023","unstructured":"Mehta, A. et al. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. J. Clin. Lipidol. 17(6), 828\u2013833. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.003 (2023).","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"93518_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hep4.1830","volume":"6","author":"M Meroni","year":"2022","unstructured":"Meroni, M. et al. Low Lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol. Commun. 6(3), 535\u2013549. https:\/\/doi.org\/10.1002\/hep4.1830 (2022).","journal-title":"Hepatol. Commun."},{"issue":"10","key":"93518_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/00015385.2022.2129183","volume":"77","author":"Z Wang","year":"2022","unstructured":"Wang, Z., Li, M. & Liu, N. The nonlinear correlation between lipoprotein (a) and the prevalence of aortic valve calcification in patients with new-onset acute myocardial infarction. Acta Cardiol. 77(10), 950\u2013959. https:\/\/doi.org\/10.1080\/00015385.2022.2129183 (2022).","journal-title":"Acta Cardiol."},{"issue":"1","key":"93518_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12944-023-01860-w","volume":"22","author":"JR Ulloque-Badaracco","year":"2023","unstructured":"Ulloque-Badaracco, J. R. et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: A systematic review and meta-analysis. Lipids Health Dis. 22(1), 98. https:\/\/doi.org\/10.1186\/s12944-023-01860-w (2023).","journal-title":"Lipids Health Dis."},{"key":"93518_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","volume":"349","author":"K Chemello","year":"2022","unstructured":"Chemello, K., Chan, D. C., Lambert, G. & Watts, G. F. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis 349, 82\u201391. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.002 (2022).","journal-title":"Atherosclerosis"},{"issue":"7","key":"93518_CR35","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.3390\/ijms23073584","volume":"23","author":"KM Kostner","year":"2022","unstructured":"Kostner, K. M. & Kostner, G. M. Lp(a) and the risk for cardiovascular disease: Focus on the Lp(a) paradox in diabetes mellitus. Int. J. Mol. Sci. 23(7), 3584. https:\/\/doi.org\/10.3390\/ijms23073584 (2022). Published 2022 Mar 25.","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"93518_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/diacare.18.2.193","volume":"18","author":"SM Haffner","year":"1995","unstructured":"Haffner, S. M. et al. Insulin sensitivity and Lp(a) concentrations in normoglycemic men. Diabetes Care. 18(2), 193\u2013199. https:\/\/doi.org\/10.2337\/diacare.18.2.193 (1995).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93518-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:44:04Z","timestamp":1741801444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93518-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93518"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93518-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted using publicly available data from the NHANES, which is collected and managed by the U.S. Centers for Disease Control and Prevention (CDC). NHANES data are de-identified and made publicly accessible, ensuring participant confidentiality. Therefore, this study did not require additional ethical approval or informed consent. The research followed the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"8538"}}